| 5-hydroxytryptamine (serotonin) receptor 1A |
PROMAZINE |
Serotonin 5-HT1A |
72% |
5.172uM |
2.955uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
VX-745 |
Adrenergic, Norepinephrine Transporter |
72% |
20.404uM |
20.236uM |
View
|
| opioid receptor, sigma 1 |
PAROXETINE |
Sigma1 |
72% |
5.366uM |
2.255uM |
View
|
| tachykinin receptor 2 |
METERGOLINE |
Tachykinin NK2 |
72% |
4.071uM |
1.357uM |
View
|
| adrenergic receptor, alpha 1b |
PERGOLIDE |
Adrenergic alpha1B |
72% |
2.622uM |
1.452uM |
View
|
| adrenergic receptor, alpha 2a |
PRAZOSIN |
Adrenergic alpha2A |
72% |
2.638uM |
.989uM |
View
|
| adrenergic receptor, alpha 2a |
METOCLOPRAMIDE |
Adrenergic alpha2A |
72% |
2.721uM |
1.02uM |
View
|
| melanocortin 5 receptor |
ECONAZOLE |
Melanocortin MC5 |
72% |
39.538uM |
37.089uM |
View
|
| Protein-tyrosine kinase, Fyn |
EPIRUBICIN |
Protein Tyrosine Kinase, Fyn |
72% |
5.181uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
KETOCONAZOLE |
Serotonin 5-HT1B |
72% |
13.539uM |
6.154uM |
View
|
| adrenergic receptor, alpha 1b |
DEXCHLORPHENIRAMINE |
Adrenergic alpha1B |
72% |
15.56uM |
8.613uM |
View
|
| Sigma-2 Receptor |
LEVAMISOLE |
Sigma2 |
72% |
4.392uM |
2.703uM |
View
|
| phosphodiesterase 5A, cGMP-specific |
LY-294002 |
Phosphodiesterase PDE5 |
72% |
9.614uM |
NoneNone |
View
|
| phosphodiesterase 5A, cGMP-specific |
LY-294002 |
Phosphodiesterase PDE5 |
72% |
9.614uM |
NoneNone |
View
|
| opioid receptor, kappa 1 |
DANAZOL |
Opiate kappa |
72% |
15.518uM |
6.207uM |
View
|
| A3 adenosine receptor |
DANAZOL |
Adenosine A3 |
72% |
11.16uM |
6.309uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
ESTRONE |
Serotonin Transporter |
72% |
5.301uM |
2.816uM |
View
|
| androgen receptor |
FLUTAMIDE |
Testosterone |
72% |
13.39uM |
8.927uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
BETA-ESTRADIOL 3-BENZOATE |
Serotonin 5-HT2B |
72% |
11.565uM |
7.359uM |
View
|
| melanocortin 5 receptor |
CHLORPROMAZINE |
Melanocortin MC5 |
72% |
7.617uM |
7.145uM |
View
|
| chemokine (C-C motif) receptor 2 |
AMIODARONE |
Chemokine CCR2B |
72% |
11.086uM |
4.285uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
LOVASTATIN |
Calcium Channel Type L, Phenylalkylamine |
72% |
6.318uM |
6.142uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
L-744832 |
Calcium Channel Type L, Dihydropyridine |
70% |
4.501uM |
2.893uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
L-744832 |
Calcium Channel Type L, Dihydropyridine |
70% |
4.501uM |
2.893uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
L-744832 |
Calcium Channel Type L, Dihydropyridine |
70% |
4.501uM |
2.893uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
L-744832 |
Calcium Channel Type L, Dihydropyridine |
70% |
4.501uM |
2.893uM |
View
|
| adrenergic receptor, alpha 2b |
QUINACRINE |
Adrenergic alpha2C |
70% |
3.857uM |
.56uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
QUINACRINE |
Adrenergic alpha2C |
70% |
3.857uM |
.56uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
QUINACRINE |
Calcium Channel Type L, Benzothiazepine |
70% |
1.076uM |
.956uM |
View
|
| adrenergic receptor, alpha 2a |
DIMENHYDRINATE |
Adrenergic alpha2A |
70% |
4.313uM |
1.617uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
PIPAMAZINE |
Serotonin 5-HT1B |
70% |
3.007uM |
1.367uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 5B |
EPIRUBICIN |
Serotonin 5-HT4 |
70% |
7.935uM |
1.323uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 4 |
EPIRUBICIN |
Serotonin 5-HT4 |
70% |
7.935uM |
1.323uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type III, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type I, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type II, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type X, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage gated, type VIII, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type IV, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type II, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type I, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type III, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type II, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type I, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type IV, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel associated protein 1 |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel associated protein 2 |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type III, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| amiloride-sensitive cation channel 5, intestinal |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type III, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type I, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type II, beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, nonvoltage-gated 1 beta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, voltage-gated, type XI, alpha |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| sodium channel, nonvoltage-gated 1, delta |
MEDROXYPROGESTERONE ACETATE |
Sodium Channel, Site 2 |
68% |
14.954uM |
13.407uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
BUSPIRONE |
Serotonin 5-HT2C |
68% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
(S)-(-)-PINDOLOL |
Dopamine Transporter |
68% |
NoneNone |
NoneNone |
View
|
| cannabinoid receptor 1 (brain) |
NITRENDIPINE |
Cannabinoid CB1 |
68% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 3 |
TERCONAZOLE |
Muscarinic M3 |
68% |
14.537uM |
3.081uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
DAUNORUBICIN |
Serotonin 5-HT1B |
68% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 1, member B4 (aldose reductase) |
FLUVASTATIN |
Aldose Reductase |
68% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 1, member B1 (aldose reductase) |
FLUVASTATIN |
Aldose Reductase |
68% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
FLUVASTATIN |
Aldose Reductase |
68% |
NoneNone |
NoneNone |
View
|
| aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
FLUVASTATIN |
Aldose Reductase |
68% |
NoneNone |
NoneNone |
View
|
| nuclear receptor subfamily 3, group C, member 1 |
ETHYNODIOL DIACETATE |
Glucocorticoid |
68% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
PIPAMAZINE |
Dopamine Transporter |
68% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-1A2 monooxygenase |
MICONAZOLE |
CYP450-1A2 Inhibition |
68% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 4 subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 3 subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
OXICONAZOLE |
Calcium Channel Type L, Benzothiazepine |
67% |
NoneNone |
NoneNone |
View
|
| nuclear receptor subfamily 3, group C, member 1 |
CORTISONE |
Glucocorticoid |
72% |
2.378uM |
1.081uM |
View
|
| adrenergic receptor, alpha 1a |
BUSPIRONE |
Adrenergic alpha1A |
72% |
3.482uM |
1.41uM |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
DOCETAXEL |
CYP450-3A4 Inhibition |
72% |
2uM |
NoneNone |
View
|
| adrenergic receptor, beta 3 |
DIHYDROERGOCRISTINE MESYLATE |
Adrenergic beta3 |
72% |
3.308uM |
2.481uM |
View
|
| cholinergic receptor, muscarinic 2 |
QUETIAPINE |
Muscarinic M2 |
72% |
3.3447uM |
1.1892uM |
View
|
| calcium channel, voltage-dependent, beta 2 subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1S subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, alpha 1F subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1D subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1C subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, beta 1 subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, L type, alpha 1E subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, N type, alpha 1B subunit |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, alpha2/delta subunit 1 |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
RALOXIFENE |
Calcium Channel Type L, Dihydropyridine |
71% |
.388uM |
.249uM |
View
|
| Cytochrom P450-2D6 monooxygenase |
SB-203580 |
CYP450-2D6 Inhibition |
71% |
2uM |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
PROPOFOL |
Serotonin 5-HT2C |
71% |
11.553uM |
6.051uM |
View
|
| solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
DOXAZOSIN |
Serotonin Transporter |
71% |
2.688uM |
1.428uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
TRIOXSALEN |
Serotonin 5-HT2C |
71% |
2.356uM |
1.234uM |
View
|
| opioid receptor, sigma 1 |
S-(-)-PROPRANOLOL |
Sigma1 |
71% |
6.665uM |
2.801uM |
View
|
| histamine receptor H 2 |
LOPERAMIDE |
Histamine H2 |
71% |
3.081uM |
3.03uM |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
LOPERAMIDE |
Serotonin 5-HT2B |
71% |
4.105uM |
2.613uM |
View
|
| prostaglandin-endoperoxide synthase 1 |
ETODOLAC |
Cyclooxygenase COX-1 |
71% |
2.649uM |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
ETODOLAC |
Cyclooxygenase COX-1 |
71% |
2.649uM |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
MITOXANTRONE |
Adrenergic, Norepinephrine Transporter |
71% |
4.9898uM |
4.9485uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, gamma 1 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, pi |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| AT hook, DNA binding motif, containing 1 (DBSS) |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, theta |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, gamma 2 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, alpha 2 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, alpha 1 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid A receptor, delta |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 |
TROPISETRON |
GABAA, Agonist Site |
71% |
3.025uM |
2.395uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 1 |
KETOTIFEN |
Calcium Channel Type L, Benzothiazepine |
71% |
2.305uM |
2.049uM |
View
|
| sodium channel associated protein 1 |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel associated protein 2 |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type III, beta |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type I, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type IX, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| sodium channel, voltage-gated, type VII, alpha |
KETOCONAZOLE |
Sodium Channel, Site 2 |
70% |
23.911uM |
21.438uM |
View
|
| thromboxane A synthase 1 |
KETOCONAZOLE |
Thromboxane Synthetase |
70% |
2.165uM |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
KETOCONAZOLE |
Thromboxane Synthetase |
70% |
2.165uM |
NoneNone |
View
|
| adrenergic receptor, beta 3 |
CIGLITAZONE |
Adrenergic beta3 |
70% |
17.871uM |
13.403uM |
View
|
| aldo-keto reductase family 1, member B4 (aldose reductase) |
KETOROLAC |
Aldose Reductase |
70% |
6.109uM |
NoneNone |
View
|
| aldo-keto reductase family 1, member B1 (aldose reductase) |
KETOROLAC |
Aldose Reductase |
70% |
6.109uM |
NoneNone |
View
|
| aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
KETOROLAC |
Aldose Reductase |
70% |
6.109uM |
NoneNone |
View
|
| aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
KETOROLAC |
Aldose Reductase |
70% |
6.109uM |
NoneNone |
View
|
| monoamine oxidase A |
NOCODAZOLE |
Monoamine Oxidase MAOA |
70% |
24.099uM |
NoneNone |
View
|
| monoamine oxidase A |
NOCODAZOLE |
Monoamine Oxidase MAOA |
70% |
24.099uM |
NoneNone |
View
|
| adenosine A2a receptor |
NOCODAZOLE |
Adenosine A2A |
70% |
7.509uM |
4.219uM |
View
|
| opioid receptor, sigma 1 |
PROGESTERONE |
Sigma1 |
70% |
3.055uM |
1.284uM |
View
|
| adrenergic receptor, alpha 2a |
AMOXAPINE |
Imidazoline I2, Central |
70% |
3.466uM |
2.31uM |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
AMOXAPINE |
Imidazoline I2, Central |
70% |
3.466uM |
2.31uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 8 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 7 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 6 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 5 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 4 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 3 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|
| calcium channel, voltage-dependent, gamma subunit 2 |
CLOTRIMAZOLE |
Calcium Channel Type L, Benzothiazepine |
70% |
28.499uM |
25.332uM |
View
|